Federal award (DEFINITIVE CONTRACT, fiscal year 2023)
Recipient: REVAGENIX INC
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2022-09-22 to 2024-06-21
Current total value of award: $4798925
Description: A NOVEL LPXC INHIBITOR WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY.